BioXcel Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.7M
Doctors Paid
2,768
Transactions
5,408
2024 Total
$5.2M
Payment Breakdown by Category
Research$8.5M (88.2%)
Consulting$420,398 (4.3%)
Food & Beverage$159,119 (1.6%)
Travel$91,244 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 161 | 88.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,983 | 184 | 4.7% |
| Consulting Fee | $420,398 | 52 | 4.3% |
| Food and Beverage | $159,119 | 4,205 | 1.6% |
| Travel and Lodging | $91,244 | 794 | 0.9% |
| Honoraria | $12,690 | 12 | 0.1% |
Payments by Type
Research
$8.5M
161 transactions
General
$1.1M
5,247 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA | $2.3M | 0 | 18 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $2.0M | 0 | 16 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $1.5M | 0 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 OF AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $1.2M | 0 | 11 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype | $457,648 | 0 | 41 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | $456,719 | 0 | 44 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $448,946 | 0 | 4 |
| EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | $91,092 | 0 | 3 |
| BXCL501401 | $81,795 | 0 | 14 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Alan Breier, Md, MD | Behavioral Neurology & Neuropsychiatry | Indianapolis, IN | $9,840 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $9,332 | $0 |
| Dr. David Seigler, M.d, M.D | Psychiatry | Riverside, CA | $8,421 | $0 |
| Ms. Amber Hoberg, Pmhnp-Bc, PMHNP-BC | Psychiatric/Mental Health | San Antonio, TX | $6,248 | $0 |
| Leon Ravin, M.d, M.D | Psychiatry | Pittsburgh, PA | $6,066 | $0 |
| Rakesh Amin, M.d, M.D | Psychiatry | Nashville, TN | $5,238 | $0 |
| Dr. Marc Martel, M.d, M.D | Emergency Medicine | Minneapolis, MN | $5,195 | $0 |
| Dr. Mary Moller, Dnp, Aprn, Pmhcns-Bc, DNP, APRN, PMHCNS-BC | Psychiatric/Mental Health, Adult | Tacoma, WA | $4,634 | $0 |
| Dr. Gregg Friedman, Md, MD | Psychiatry | Hallandale Beach, FL | $3,632 | $0 |
| Robert Berman, Md, MD | Psychiatry | New Haven, CT | $3,000 | $0 |
| Charles Nemeroff, Md Phd, MD PHD | Psychiatry | Austin, TX | $2,680 | $0 |
| Jeffrey Cummings, Md, MD | Neurology | Los Angeles, CA | $2,180 | $0 |
| Charles Pollack, Md, MD | Emergency Medicine | Roswell, GA | $1,868 | $0 |
| Robert Findling, Md, MD | Child & Adolescent Psychiatry | Cleveland, OH | $1,575 | $0 |
| Dr. Matthew Berger, Md, MD | Psychiatry | Moosic, PA | $1,215 | $0 |
| Dr. Daniel Zelinski, M.d., Ph.d, M.D., PH.D | Emergency Medicine | Hilliard, OH | $1,050 | $0 |
| Rose Knapp, Np, NP | Nurse Practitioner | Long Branch, NJ | $905.00 | $0 |
| Dr. Marc Agronin, M.d, M.D | Psychiatry | Miami, FL | $500.00 | $0 |
| Michael Bernot, M.d, M.D | Psychiatry | Old Westbury, NY | $475.99 | $0 |
| Dr. Anthony Lujack, M.d, M.D | Psychiatry | New York, NY | $462.58 | $0 |
| Richard Jackson, Md, MD | Family Medicine | Ronks, PA | $403.15 | $0 |
| Joseph Miller, M.d, M.D | Pediatric Radiology | Los Angeles, CA | $403.15 | $0 |
| Pratik Mehta, Md, MD | Psychiatry | Los Angeles, CA | $403.15 | $0 |
| Dr. Tara Howard, N.p. , Dnp, N.P. , DNP | Nurse Practitioner | New York, NY | $391.85 | $0 |
| James Eyerman, Md, MD | Psychiatry | San Francisco, CA | $377.24 | $0 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. has made $9.7M in payments to 2,768 healthcare providers, recorded across 5,408 transactions in the CMS Open Payments database. In 2024, the company paid $5.2M. The top product by payment volume is IGALMI ($8.7M).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Psychiatry ($395,547 to 540 doctors).
Payment categories include: Food & Beverage ($159,119), Consulting ($420,398), Research ($8.5M), Travel & Lodging ($91,244).
BioXcel Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.